We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Effect of Vidarabine on Chronic Hepatitis B Virus Infection

Richard B. Pollard, MD; Joseph L. Smith, MD; E. Andrew Neal, MD; Peter B. Gregory, MD; Thomas C. Merigan, MD; William S. Robinson, MD
JAMA. 1978;239(16):1648-1650. doi:10.1001/jama.1978.03280430064020.
Text Size: A A A
Published online


SERA of patients with hepatitis B virus (HBV) infection contain several viral forms. The development of reproducible assays for these markers facilitates the evaluation of intervention with antiviral agents. Human leukocyte interferon, given systemically to patients with chronic HBV infection, resulted in a decrease in the Dane particle markers core antigen (HBcAg), DNA polymerase, and the e antigen (HBeAg) to undetectable levels in the serum.1 The hepatitis B surface antigen (HBsAg) level also decreased in two interferon-treated patients.

Vidarabine (adenine arabinoside), a purine nucleoside that inhibits replication of certain DNA viruses in tissue culture, has been administered to humans in an attempt to alter the course of various herpesvirus infections. Herpes simplex encephalitis patients treated with vidarabine had a significantly reduced mortality in a recent report.2 Toxic reactions with this agent have been minimal at the dosage used in the reported studies.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.